Biotech market spotlight: Mesoblast
Monday, 09 November, 2009
Regenerative medicine company, Mesoblast (ASX:MSB), has seen some fluctuating share prices over the past week, with it lifting 9.4% since last Monday's open, although it's down 3.3% in today's trading.
On Friday the company announced the latest in a series of successful trials of its stem cell treatments targeted at regenerating and repairing bone and cartilage.
The technology uses mesenchymal precursor cells (MPC), which are a form of adult stem cell that can generate new bone, cartilage, and blood vessels.
Friday's announcement concerned a study involving 18 patients who received bone marrow transplants using umbilical cord blood expanded by MPCs. These patients experienced faster recovery times and lower rates of graft-versus-host disease.
Mesoblast is currently at $1.16, down 4c or 3.33% at the close of trading on Monday evening.
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
